Hershey's Is Making a Big Change to Its Products
But in April, Health and Human Services Secretary Robert F. Kennedy Jr. started putting the pressure on to do more, asking companies to stop using the dyes Green No. 3, Red No. 40, Yellows No. 5 and 6, and Blues No. 1 and 2, all while noting that he also hopes to officially remove Citrus Red No. 2 and Orange B from shelves soon.
Now, food makers are beginning to take aggressive action. For example, Kraft Heinz has resolved to remove all synthetic colors from its products by 2027. That includes brands known for their fun hues like Jell-O, Kool-Aid, Jet-Puffed, and Crystal Light. Others that have recently jumped on the bandwagon include giants Conagra Foods and Nestlé USA. The latter is an overachiever, saying its target is months before the official deadline.
The latest to join the march toward natural colors? Hershey.
OK, chocolate is naturally brown, so no problem there, right? But don't forget Hershey's many other tasty assets. The company's products include Jolly Rancher, Twizzlers, and Bubble Yum, all noted for their variety of bright shades.
Hershey declined to comment to Allrecipes, but a spokesperson told Bloomberg News, "Removing these colors is a natural next step in our program to ensure consumers have options to fit their lifestyle while maintaining trust and confidence in our products." The company plans to remove the synthetic colors by the end of 2027.
A Hershey representative told Food Dive that a 'strong national food ingredient approval system is the best way to ensure food safety, affordability, and quality in the marketplace.'
Translation? As states, including Texas and West Virginia, begin to make their own rules for manufacturers, a big, national push will be easier for everyone and will ultimately save the company money. We can't wait to see what Jolly Rancher candies will look like in 2027.
Read the original article on ALLRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Your Guide To Navigating Perimenopause In Your 30s And Beyond
The first time I heard the word "perimenopause," I felt like I had been late to a party I wasn't invited to. Don't get me wrong—it's not a party I'm dying to go to, but I couldn't believe how little I knew about such a pivotal reproductive life stage. And I'm not alone. When I set out to report on this often overlooked and misunderstood phase of life, nearly a dozen women I spoke to initially had zero clue that perimenopause could be the root of their sudden and varied symptoms. They also had no idea it can last anywhere from two to 10 years (sometimes more), it's characterized by a fluctuation of hormones (not necessarily a sharp decline), and, perhaps most significantly, it can start as early as your mid-thirties (I couldn't believe it either). The good news is there's more awareness than ever around perimenopause, thanks to a growing call for menopause education, millennials' track record of breaking taboos, and a little thing called the social media algorithm. And we hope this series of stories, below, contributes to that. You'll find a special report on millennials and perimenopause, real stories from women on how they successfully manage their peri symptoms, hormonal and non-hormonal treatment options, where to actually find good care, tips on how to stay healthy in peri and beyond, and how to advocate for menopause policy in your state. Our grandmothers and mothers may not have had the word to describe this phase of life, but we do. And the more prepared we are for it, the better (and healthier) we are. Read the stories, share them with your friends, and let us know what you think in the comments—this is only the beginning of the conversation. Read The StoriesMillennials Are Entering The Perimenopause Chat READ THE STORYYour Brain (And Heart) On Hot Flashes READ THE STORYHow Young Is Too Young For Hormone Therapy? READ THE STORYHow These Women Are Successfully Managing Their Perimenopause Symptoms READ THE STORYWhere To Actually Find Good Perimenopause Care READ THE STORYHow To Stay Healthy In Perimenopause And Beyond READ THE STORYWe Need To Fight For Menopause Policy Now More Than Ever READ THE STORY This story appears in the Summer 2025 issue of Women's By Heami LeeProp Styling By Christine Keely You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
